Sign In
Buy ABBV
$224.93
+7.86 (+3.62%)
At Close: Jun 04, 2026
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
05:41am, Saturday, 05'th Jul 2025
There's a strong parallel between investing for passive income and planting an apple tree. Both require some work up front.
Is It Worth Investing in AbbVie (ABBV) Based on Wall Street's Bullish Views?
10:30am, Thursday, 03'rd Jul 2025
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often
AbbVie Stock At $190: Premium Pricing For A Transformation Story
10:50am, Wednesday, 02'nd Jul 2025
AbbVie (NASDAQ:ABBV) has distinguished itself as one of the top performers in the healthcare sector this year, with its stock rising by 6% while the broader S&P 500 healthcare index fell by 1%. This o
Why AbbVie (ABBV) is a Top Value Stock for the Long-Term
10:46am, Wednesday, 02'nd Jul 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Will AbbVie's Acquisition Spree Aid Pipeline Growth?
09:51am, Wednesday, 02'nd Jul 2025
ABBV's $2.1 billion Capstan deal and 20+ recent acquisitions sharpen its pipeline edge across immunology and beyond.
ABBV to Boost Immunology Pipeline With Capstan Buyout for $2.1B
11:05am, Tuesday, 01'st Jul 2025
AbbVie's $2.1 billion Capstan deal brings a novel in-vivo CAR-T therapy and tLNP platform to boost its immunology pipeline.
Seeing Machines gains traction as Mitsubishi expands Gen 3 rollout
10:30am, Monday, 30'th Jun 2025
Seeing Machines Ltd (AIM:SEE, OTC:SEEMF), the UK-listed tech firm specialising in driver monitoring systems, is picking up speed with its next-generation aftermarket product. Stifel notes that the Gua
Abbvie confirms $2.1bn Capstan swoop
09:19am, Monday, 30'th Jun 2025
Abbvie Inc (NYSE:ABBV) has agreed to acquire Capstan Therapeutics in a deal worth up to $2.1 billion, expanding its pipeline with a potential first-in-class treatment for autoimmune diseases and gaini
AbbVie to buy Capstan Therapeutics for up to $2.1 billion
08:42am, Monday, 30'th Jun 2025
AbbVie said on Monday it will acquire Capstan Therapeutics in a deal worth up to $2.1 billion, adding experimental treatments for autoimmune diseases to its portfolio.
AbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology
08:31am, Monday, 30'th Jun 2025
Capstan's lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo, and is
SKINVIVE by JUVÉDERM® is currently approved in the U.S. as the first and only hyaluronic acid microdroplet injectable indicated to improve cheek skin smoothness. If approved, SKINVIVE by JUVÉDERM
AbbVie to Host Second-Quarter 2025 Earnings Conference Call
08:00am, Monday, 30'th Jun 2025
NORTH CHICAGO, Ill. , June 30, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its second-quarter 2025 financial results on Thursday, July 31, 2025, before the market opens.
This Changes Everything: One Of The Most Important Shifts For Dividend Investors
07:30am, Monday, 30'th Jun 2025
Inflation isn't just back, it's becoming policy. From skewed CPI data to deficit-driven dollar moves, we're entering a new and lasting macro era. The U.S. may now prefer higher inflation to fix its ba
Best Dividend Aristocrats For July 2025
07:19am, Sunday, 29'th Jun 2025
Dividend Aristocrats have underperformed the S&P 500 in 2025, with NOBL up 1.77% versus SPY's 5.55% year-to-date gain. Dividend growth remains healthy, with 44 out of 69 Aristocrats already raising pa
3 Dividend Stocks to Double Up on Right Now
04:51am, Sunday, 29'th Jun 2025
Buy, sell, or hold? That's the question investors must continually ask about each stock in their portfolio.
